{
  "actions": [
    {
      "acted_at": "2013-04-15", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Energy and Commerce.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2013-04-19", 
      "in_committee": null, 
      "references": [], 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hres161-113", 
  "bill_type": "hres", 
  "committees": [
    {
      "activity": [
        "referral", 
        "in committee"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }
  ], 
  "congress": "113", 
  "cosponsors": [
    {
      "district": "4", 
      "name": "Aderholt, Robert B.", 
      "sponsored_at": "2013-04-15", 
      "state": "AL", 
      "thomas_id": "01460", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "11", 
      "name": "Grimm, Michael G.", 
      "sponsored_at": "2013-04-15", 
      "state": "NY", 
      "thomas_id": "02041", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "9", 
      "name": "Keating, William R.", 
      "sponsored_at": "2013-04-15", 
      "state": "MA", 
      "thomas_id": "02025", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "8", 
      "name": "Lynch, Stephen F.", 
      "sponsored_at": "2013-04-15", 
      "state": "MA", 
      "thomas_id": "01686", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "3", 
      "name": "Rahall, Nick J., II", 
      "sponsored_at": "2013-04-15", 
      "state": "WV", 
      "thomas_id": "00940", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "6", 
      "name": "Tierney, John F.", 
      "sponsored_at": "2013-04-15", 
      "state": "MA", 
      "thomas_id": "01535", 
      "title": "Rep", 
      "withdrawn_at": null
    }, 
    {
      "district": "10", 
      "name": "Wolf, Frank R.", 
      "sponsored_at": "2013-04-15", 
      "state": "VA", 
      "thomas_id": "01238", 
      "title": "Rep", 
      "withdrawn_at": null
    }
  ], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2013-04-15", 
  "number": "161", 
  "official_title": "Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.", 
  "popular_title": null, 
  "related_bills": [
    {
      "bill_id": "sres97-113", 
      "reason": "related", 
      "type": "bill"
    }
  ], 
  "short_title": null, 
  "sponsor": {
    "district": "5", 
    "name": "Rogers, Harold", 
    "state": "KY", 
    "thomas_id": "00977", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2013-04-15", 
  "subjects": [
    "Drug safety, medical device, and laboratory regulation", 
    "Drug, alcohol, tobacco use", 
    "Health", 
    "Prescription drugs"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced", 
    "date": "2013-04-15", 
    "text": "Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.", 
      "type": "official"
    }
  ], 
  "updated_at": "2013-11-03T11:01:59-05:00"
}